Elan to pay $203.5M for marketing misdeeds

Elan has joined the marketing-settlement club. The Irish drugmaker has agreed to pay $203.5 million to settle U.S. government probes into its sales and marketing tactics on the epilepsy drug Zonegran. As part of the deal, Elan's U.S. subsidiary will plead guilty to a misdemeanor violation. Another part: A corporate integrity agreement with the HHS Inspector General.

The settlement with the U.S. Attorney's Office in Massachusetts hasn't been finalized, Elan emphasizes in a statement, but the company expects to work out an acceptable integrity agreement and get the government's seal of approval for the deal. Other details weren't available.

The $203.5 million Elan will pay is just a fraction of the other marketing settlements we've seen recently. Pfizer agreed to pay $2.3 billion to resolve an off-label marketing probe, including a $1.2 billion criminal fine, the largest in U.S. history. Eli Lilly paid $1.42 billion to settle similar claims about its marketing of Zyprexa.

- read the Elan release
- see the news from Reuters

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.